PE20241236A1 - Composiciones y metodos para tratar pacientes con demencia debida a la enfermedad de alzheimer con una combinacion de thc y melatonina - Google Patents

Composiciones y metodos para tratar pacientes con demencia debida a la enfermedad de alzheimer con una combinacion de thc y melatonina

Info

Publication number
PE20241236A1
PE20241236A1 PE2024000480A PE2024000480A PE20241236A1 PE 20241236 A1 PE20241236 A1 PE 20241236A1 PE 2024000480 A PE2024000480 A PE 2024000480A PE 2024000480 A PE2024000480 A PE 2024000480A PE 20241236 A1 PE20241236 A1 PE 20241236A1
Authority
PE
Peru
Prior art keywords
compositions
thc
compound
melatonin
methods
Prior art date
Application number
PE2024000480A
Other languages
English (en)
Spanish (es)
Inventor
Ramachandra Mukunda
Jagadeesh S Rao
Original Assignee
Igc Pharma Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igc Pharma Ip Llc filed Critical Igc Pharma Ip Llc
Publication of PE20241236A1 publication Critical patent/PE20241236A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9066Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PE2024000480A 2021-09-17 2022-09-16 Composiciones y metodos para tratar pacientes con demencia debida a la enfermedad de alzheimer con una combinacion de thc y melatonina PE20241236A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163245799P 2021-09-17 2021-09-17
PCT/US2022/076579 WO2023044433A1 (en) 2021-09-17 2022-09-16 Compositions and methods for treating patients with dementia due to alzheimer's disease with a combination of thc and melatonin

Publications (1)

Publication Number Publication Date
PE20241236A1 true PE20241236A1 (es) 2024-06-19

Family

ID=83688895

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024000480A PE20241236A1 (es) 2021-09-17 2022-09-16 Composiciones y metodos para tratar pacientes con demencia debida a la enfermedad de alzheimer con una combinacion de thc y melatonina

Country Status (8)

Country Link
US (1) US20250275935A1 (https=)
EP (1) EP4401717A1 (https=)
JP (1) JP2024535871A (https=)
CA (1) CA3232209A1 (https=)
CL (1) CL2024000782A1 (https=)
CO (1) CO2024004628A2 (https=)
PE (1) PE20241236A1 (https=)
WO (1) WO2023044433A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773527A4 (en) 2018-03-30 2022-04-13 India Globalization Capital, Inc. METHOD AND COMPOSITION FOR THE TREATMENT OF CNS DISEASES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR44305E (fr) 1933-12-09 1934-12-24 Meaf Mach En Apparaten Fab Nv Circuits de voie à rails sans potentiel ou portés au même potentiel
US11065225B1 (en) 2015-07-30 2021-07-20 University Of South Florida Ultra-low dose THC as a potential therapeutic and prophylactic agent for Alzheimer's disease
EP3538122B1 (en) * 2016-11-14 2025-03-26 Farm To Farma, Inc. Cannabinoid formulations and method of making the same
EP3582755A4 (en) * 2017-02-15 2020-12-23 Molecular Infusions, LLC PREPARATIONS
WO2019036243A1 (en) * 2017-08-16 2019-02-21 Molecular Infusions, Llc Formulations
US20200246404A1 (en) * 2017-02-15 2020-08-06 Molecular Infusions, Llc Formulations
EP3773527A4 (en) 2018-03-30 2022-04-13 India Globalization Capital, Inc. METHOD AND COMPOSITION FOR THE TREATMENT OF CNS DISEASES
WO2021011421A1 (en) * 2019-07-12 2021-01-21 University Of South Florida Compositions and methods for treating alzheimers disease

Also Published As

Publication number Publication date
WO2023044433A1 (en) 2023-03-23
JP2024535871A (ja) 2024-10-02
CO2024004628A2 (es) 2024-05-10
US20250275935A1 (en) 2025-09-04
CA3232209A1 (en) 2023-03-23
EP4401717A1 (en) 2024-07-24
CL2024000782A1 (es) 2024-09-23

Similar Documents

Publication Publication Date Title
Farokhnia et al. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study
CL2021003452A1 (es) Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades.
CO2022004902A2 (es) Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
MX2017011280A (es) Terapia neuro-afectiva regional topica con cannabinoides.
MX2021015499A (es) Derivados de 2h-indazol y su uso en el tratamiento de enfermedades.
CR20220250A (es) Métodos para el tratamiento de trastornos depresivos
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
MX2022014199A (es) Usos y formulaciones de los cannabinoides.
BR112015029897A2 (pt) composição sólida para administração oral contendo ácido ibandrônico ou um seu sal farmaceuticamente aceitável e vitamina d e processo para obtenção da referida composição
CL2023001580A1 (es) Uso de roluperidona para tratar síntomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroprotección
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
MX2019002047A (es) Metodos y composiciones para tratar infecciones fungicas cutaneas.
PE20241236A1 (es) Composiciones y metodos para tratar pacientes con demencia debida a la enfermedad de alzheimer con una combinacion de thc y melatonina
EP2424536A4 (en) NEW PHOTOSENSIBILIZER FORMULATIONS FOR ORAL ADMINISTRATION
MX2023002350A (es) Composiciones y metodos para mejorar enfermedades y trastornos neurologicos.
CO2024013759A2 (es) Composición que comprende n-acetilcisteína, vitamina d y preferentemente glutatión, usos de la misma, y composiciones farmacéuticas y nutracéuticas de los mismos
MX2023007510A (es) Derivados de 2h-indazol como inhibidores de irak4 y su uso en el tratamiento de enfermedades.
EA028540B1 (ru) Применение адсорбированного гомогената трутневого расплода и витамина dили витаминов группы d и/или их активных метаболитов для профилактики и лечения вирусных заболеваний
Kumar Neurotherapeutic Potential of Withania somnifera: Insights from Ayurvedic Medicine
MX2022002451A (es) Metodos para el tratamiento de la enfermedad cln2 en sujetos pediatricos.
Bano et al. Effectiveness of melatonin supplementation in preventing cognitive decline among older adults with sleep disorders: a narrative review
Cosentino et al. New approach for treatment of radiotherapy-induced peripheral neuropathy: a pilot observational study
CN111315238A (zh) 用于减轻由衰老引起的女性病症的补充剂
MX2025012013A (es) Protac de irak4